atherosclerotic cardiovascular disease

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

LPA2 antagonist 3 (compound 15) serves as an Lp(a) antagonist. Lp(a) is a pathogenic risk factor for atherosclerotic cardiovascular disease (ASCVD).

Anti-oxLDL Antibody is a specific monoclonal antibody targeting oxidized low-density lipoprotein (oxLDL). As oxLDL is a key pro-inflammatory factor promoting atherosclerotic plaque formation and vessel wall inflammation, this antibody is frequently used to study the pathological mechanisms of cardiovascular disease, plaque stability, and the development of diagnostic assays by neutralizing oxLDL or blocking its interaction with macrophage receptors (e.g., CD36).